We are live on
!
Find out more
BC
Broadfin Capital Portfolio holdings
AUM
$747M
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter
Est. Return
+19.43%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$676M
AUM Growth
-$147M
(-18%)
Cap. Flow
-$211M
Cap. Flow
% of AUM
-31.23%
Top 10 Holdings %
Top 10 Hldgs %
56.25%
Holding
63
New
9
Increased
11
Reduced
18
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ENDP
Endo International plc
ENDP
|
+$17M |
| 2 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
+$6.02M |
| 3 |
Zimmer Biomet
ZBH
|
+$5.83M |
| 4 |
RGLS
Regulus Therapeutics
RGLS
|
+$4.5M |
| 5 |
Baxter International
BAX
|
+$4.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$25.2M |
| 2 |
Heron Therapeutics
HRTX
|
+$15.1M |
| 3 |
RXDX
Ignyta, Inc.
RXDX
|
+$14.9M |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$13.4M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$12.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| – | – |
-1,000,000
| Closed | -$77.2M |
|
|
ENDP
52
CALL
DELISTED
Endo International plc
ENDP
| – | – |
-2,000,000
| Closed | -$22.3M |
|
|
PGNX
53
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| – | – |
-1,000,000
| Closed | -$6.79M |
|
|
HZNP
54
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-1,000,000
| Closed | -$11.9M |
|
|
ELGX
55
DELISTED
Endologix Inc
ELGX
| – | – |
-77,934
| Closed | -$3.79M |
|
|
JUNO
56
DELISTED
Juno Therapeutics, Inc.
JUNO
| – | – |
-262,100
| Closed | -$7.83M |
|
|
DXTR
57
DELISTED
Dextera Surgical Inc.
DXTR
| – | – |
-987,520
| Closed | -$296K |
|
|
NVDQ
58
DELISTED
Novadaq Technologies Inc.
NVDQ
| – | – |
-1,000,000
| Closed | -$11.7M |
|
|
NVET
59
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
| – | – |
-1,127,200
| Closed | -$7.54M |
|
|
ARLZ
60
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
| – | – |
-2,034,103
| Closed | -$2.75M |
|
|
LJPC
61
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
| – | – |
-150,000
| Closed | -$4.47M |
|
Similar funds
CBU
CONA
MP
SC
KGACF
BPWA
TRAM
VMI
Broadfin Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Broadfin Capital held 63 positions worth $676M, down 18% from $823M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Broadfin Capital withdrew a net $211M in Q3 2017, closing 18 positions and reducing 18 holdings. Its most notable exit was Novadaq Technologies Inc., an estimated $11.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 75% a quarter earlier.
Against the trend, Broadfin Capital opened a new position in Tetraphase Pharmaceuticals, Inc. worth $6.16M.
- Broadfin Capital's largest Q3 2017 buy was Tetraphase Pharmaceuticals, Inc.: 45,000 shares worth $6.16M.
- Broadfin Capital added most to Endo International plc in Q3 2017, an estimated $17M increase.
- Broadfin Capital's biggest Q3 2017 reduction was Travere Therapeutics, cutting an estimated $25.2M.
- Broadfin Capital fully exited Novadaq Technologies Inc. in Q3 2017, selling an estimated $11.7M.
- Broadfin Capital's ten largest holdings make up 56% of its $676M portfolio in Q3 2017.
- Broadfin Capital opened 9 new positions and closed 18 in Q3 2017.
- Broadfin Capital's portfolio value fell 18% quarter-over-quarter to $676M.
Based on Broadfin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.